ODE V
This article was originally published in The Rose Sheet
Executive Summary
Jonca Bull, MD, appointed deputy director, FDA Office of Drug Evaluation V, responsible for OTCs. Bull will report to ODE V Director Robert DeLap, MD/PhD, effective July 30. Debra Bowen, MD, left the position early this year to join McNeil Consumer Healthcare as VP-clinical research (1"The Rose Sheet" Jan. 3, p. 13). Currently acting director of the Office of Women's Health, Bull previously worked in the Office of the Commissioner as a special assistant and medical advisor to the deputy commissioner for operations. She joined FDA in 1994
You may also be interested in...
ODE V Deputy Director Bowen Leaves FDA For McNeil Position
FDA Center for Drug Evaluation & Research Office of Drug Evaluation V Deputy Director Debra Bowen, MD, has left the agency to become McNeil's VP-Clinical Research.
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle